Evolus Enters European Aesthetic Market with CE Certification for Estyme® Dermal Filler

Evolus Marks Entry into European Aesthetic Market with CE Mark Certification for Estyme®

Evolus, Inc., a prominent player in the performance beauty sector, achieves a significant milestone by securing EU Medical Device Regulation (MDR) certification for its injectable hyaluronic acid (HA) gels under the brand name Estyme®. This certification not only permits Evolus to enter the lucrative dermal filler market but also expands its global footprint, targeting an estimated market potential of $1.8 billion outside the United States. The CE Mark, awarded after a rigorous evaluation process, confirms that Evolus's products meet high standards for safety, efficacy, and quality, a critical factor for success in the competitive aesthetic industry.

The introduction of Estyme® marks a pivotal development for Evolus, allowing the company to commence a limited experience program with selected physician partners. Through this initiative, Evolus aims to gather valuable insights that will inform a broader market launch planned for the latter half of 2025. David Moatazedi, President and CEO, underscores the importance of this certification as a testament to Evolus’s dedication to delivering high-quality aesthetic products that comply with stringent regulatory frameworks. The strategic entry into the European market positions Evolus to leverage its innovative capabilities and customer-centric approach in addressing the diverse needs of beauty consumers.

Dr. Rui Avelar, Chief Medical Officer and Head of R&D, emphasizes that Estyme® embodies significant innovation through its proprietary cold technology and advanced cross-linking techniques. These advancements not only enhance the natural HA chain but also differentiate Estyme® from existing products in the market, suggesting a competitive edge for Evolus as it ventures into this new territory. In tandem with its European strategy, Evolus is poised for U.S. approval and the anticipated launch of Evolysse™, further solidifying its ambition to become a leading global multi-product aesthetic company.

In addition to the launch of Estyme®, Evolus continues to focus on developing a robust customer-centric model and an innovative digital platform. This strategic emphasis enables the company to engage effectively with the next generation of beauty consumers, ensuring that its offerings resonate with evolving market demands. With the industry's landscape continually shifting, Evolus remains committed to enhancing its product portfolio and expanding its market reach.

As Evolus embarks on this new chapter, the successful certification of Estyme® signals not only a growth opportunity but also a commitment to innovation within the aesthetic sector. The company’s strategic initiatives position it favorably in a competitive market landscape, aiming to set new benchmarks for quality and efficacy in beauty products.